Reverse warburg effect in a patient with aggressive B-cell lymphoma: Is lactic acidosis a paraneoplastic syndrome?

Seminars in Oncology

Volumn 40, Issue 4, 2013, Pages 403-418

  Martinez Outschoorn, Ubaldo E ^a   Whitaker Menezes, Diana ^a   Valsecchi, Matias ^a   Martinez Cantarin, Maria P ^a   Dulau Florea, Alina ^a   Gong, Jerald ^a   Howell, Anthony ^a   Flomenberg, Neal ^a   Pestell, Richard G ^a   Wagner, John ^a   Arana Yi, Cecilia ^a   Sharma, Manish ^a   Sotgia, Federica ^a   Lisanti, Michael P ^a  

^a MOUNT SINAI HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBON DIOXIDE; LACTATE DEHYDROGENASE; LACTIC ACID; METFORMIN; PYRUVIC ACID; WATER;

ANION GAP; ASCITES FLUID; B LYMPHOCYTE; BLOOD PH; CANCER PATIENT; CANCER PROGNOSIS; CANCER RECURRENCE; CARDIOGENIC SHOCK; CRITICALLY ILL PATIENT; CYTOLOGY; DISSEMINATED INTRAVASCULAR CLOTTING; EVENT FREE SURVIVAL; FLOW CYTOMETRY; FLUORESCENCE IN SITU HYBRIDIZATION; GERMINAL CENTER; GLYCOLYSIS; HEPATITIS C; HUMAN; HYPERTENSION; HYPOVOLEMIA; IMMUNOHISTOCHEMISTRY; INDUCTION CHEMOTHERAPY; LACTIC ACIDOSIS; LARGE CELL LYMPHOMA; LUNG AUSCULTATION; LUNG HEMORRHAGE; LYMPH NODE BIOPSY; MITOCHONDRIAL RESPIRATION; MITOCHONDRION; OXIDATIVE PHOSPHORYLATION; OXIDATIVE STRESS; OXYGEN SATURATION; PARANEOPLASTIC SYNDROME; PHYSICAL EXAMINATION; PORTAL HYPERTENSION; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REVIEW; SEPSIS; SURVIVAL RATE; TUMOR MICROENVIRONMENT;

EID: 84883180702     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2013.04.016     Document Type: Article

References (112)

1. D. Luft, G. Deichsel, R.M. Schmulling, W. Stein, and M. Eggstein Definition of clinically relevant lactic acidosis in patients with internal diseases Am J Clin Pathol 80 4 1983 484 489
2. P.J. Fall, and H.M. Szerlip Lactic acidosis: from sour milk to septic shock J Intensive Care Med 20 5 2005 255 271
3. J.P. Ruiz, A.K. Singh, and P. Hart Type B lactic acidosis secondary to malignancy: case report, review of published cases, insights into pathogenesis, and prospects for therapy ScientificWorldJournal 11 2011 1316 1324
4. F.H. Chan, D. Carl, and L.J. Lyckholm Severe lactic acidosis in a patient with B-cell lymphoma: a case report and review of the literature Case Report Med 2009 2009 534 561
5. G.C. Doolittle, M.W. Wurster, C.S. Rosenfeld, and D.C. Bodensteiner Malignancy-induced lactic acidosis South Med J 81 4 1988 533 536
6. B.C. Keller, D. Nussensveig, and J.E. Dowell Diffuse large B-cell lymphoma in a hepatitis C virus-infected patient presenting with lactic acidosis and hypoglycemia Am J Med Sci 339 2 2010 202 204
7. E. Dogan, R. Erkoc, H. Sayarlioglu, S. Alici, I. Dilek, and O. Alici Fatal lactic acidosis due to leukemic transformation in a patient with non-Hodgkin's lymphoma: case report Adv Ther 22 5 2005 443 446
8. K.J. Gunnerson, M. Saul, S. He, and J.A. Kellum Lactate versus non-lactate metabolic acidosis: a retrospective outcome evaluation of critically ill patients Crit Care 10 1 2006 R22
9. P.W. Stacpoole Lactic acidosis and other mitochondrial disorders Metabolism 46 3 1997 306 321
10. A.S. Friedenberg, D.E. Brandoff, and F.J. Schiffman Type B lactic acidosis as a severe metabolic complication in lymphoma and leukemia: a case series from a single institution and literature review Medicine (Baltimore) 86 4 2007 225 232
11. E.M. Sillos, J.L. Shenep, G.A. Burghen, C.H. Pui, F.G. Behm, and J.T. Sandlund Lactic acidosis: a metabolic complication of hematologic malignancies: case report and review of the literature Cancer 92 9 2001 2237 2246
12. M.G. Vander Heiden, L.C. Cantley, and C.B. Thompson Understanding the Warburg effect: the metabolic requirements of cell proliferation Science 324 5930 2009 1029 1033
13. N. Bellance, P. Lestienne, and R. Rossignol Mitochondria: from bioenergetics to the metabolic regulation of carcinogenesis Front Biosci 14 2009 4015 4034
14. H. Pelicano, D.S. Martin, R.H. Xu, and P. Huang Glycolysis inhibition for anticancer treatment Oncogene 25 34 2006 4633 4646
15. M.E. Juweid, and B.D. Cheson Positron-emission tomography and assessment of cancer therapy N Engl J Med 354 5 2006 496 507
16. P. Seam, M.E. Juweid, and B.D. Cheson The role of FDG-PET scans in patients with lymphoma Blood 110 10 2007 3507 3516
17. T.L. Whiteside The tumor microenvironment and its role in promoting tumor growth Oncogene 27 45 2008 5904 5912
18. A. Gallamini Positron emission tomography scanning: a new paradigm for the management of Hodgkin's lymphoma Haematologica 95 7 2010 1046 1048
19. U.E. Martinez-Outschoorn, Z. Lin, and C. Trimmer Cancer cells metabolically "fertilize" the tumor microenvironment with hydrogen peroxide, driving the Warburg effect: implications for PET imaging of human tumors Cell Cycle 10 15 2011 2504 2520
20. U.E. Martinez-Outschoorn, R.M. Balliet, and D.B. Rivadeneira Oxidative stress in cancer associated fibroblasts drives tumor-stroma co-evolution: A new paradigm for understanding tumor metabolism, the field effect and genomic instability in cancer cells Cell Cycle 9 16 2010 3256 3276
21. K.M. Nieman, H.A. Kenny, and C.V. Penicka Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth Nat Med 17 2011 1498 1503
22. F. Sotgia, U.E. Martinez-Outschoorn, S. Pavlides, A. Howell, R.G. Pestell, and M.P. Lisanti Understanding the Warburg effect and the prognostic value of stromal caveolin-1 as a marker of a lethal tumor microenvironment Breast Cancer Res 13 4 2011 213
23. U.E. Martinez-Outschoorn, F. Sotgia, and M.P. Lisanti Power Surge: Supporting Cells "Fuel" Cancer Cell Mitochondria Cell Metab 15 1 2012 4 5
24. G.A. Brooks Cell-cell and intracellular lactate shuttles J Physiol 587 Pt 23 2009 5591 5600
25. S. Pavlides, D. Whitaker-Menezes, and R. Castello-Cros The reverse Warburg effect: aerobic glycolysis in cancer associated fibroblasts and the tumor stroma Cell Cycle 8 23 2009 3984 4001
26. S. Pavlides, I. Vera, and R. Gandara Warburg meets autophagy: cancer-associated fibroblasts accelerate tumor growth and metastasis via oxidative stress, mitophagy, and aerobic glycolysis Antioxid Redox Signal 16 2012 1264 1284
27. U.E. Martinez-Outschoorn, and C. Trimmer Autophagy in cancer associated fibroblasts promotes tumor cell survival: Role of hypoxia, HIF1 induction and NFkappaB activation in the tumor stromal microenvironment Cell Cycle 9 17 2010 3515 3533
28. Y.H. Ko, Z. Lin, N. Flomenberg, and R.G. Pestell Glutamine fuels a vicious cycle of autophagy in the tumor stroma and oxidative mitochondrial metabolism in epithelial cancer cells: Implications for preventing chemotherapy resistance Cancer Biol Ther 12 12 2011 1085 1097
29. D. Whitaker-Menezes, U.E. Martinez-Outschoorn, and N. Flomenberg Hyperactivation of oxidative mitochondrial metabolism in epithelial cancer cells in situ: visualizing the therapeutic effects of metformin in tumor tissue Cell Cycle 10 23 2011 4047 4064
30. U.E. Martinez-Outschoorn, and R.G. Pestell Energy transfer in "parasitic" cancer metabolism: Mitochondria are the powerhouse and Achilles' heel of tumor cells Cell Cycle 10 24 2011 4208 4216
31. C. Trimmer, F. Sotgia, and D. Whitaker-Menezes Caveolin-1 and mitochondrial SOD2 (MnSOD) function as tumor suppressors in the stromal microenvironment: a new genetically tractable model for human cancer associated fibroblasts Cancer Biol Ther 11 4 2011 383 394
32. T.N. Chonghaile, K.A. Sarosiek, and T.T. Vo Pretreatment mitochondrial priming correlates with clinical response to cytotoxic chemotherapy Science 334 2011 1129 1133
33. U.E. Martinez-Outschoorn, Z. Lin, and Y.H. Ko Understanding the metabolic basis of drug resistance: therapeutic induction of the Warburg effect kills cancer cells Cell Cycle 10 15 2011 2521 2528
34. U.E. Martinez-Outschoorn, A. Goldberg, and Z. Lin Anti-estrogen resistance in breast cancer is induced by the tumor microenvironment and can be overcome by inhibiting mitochondrial function in epithelial cancer cells Cancer Biol Ther 12 10 2011 924 938
35. A.K. Witkiewicz, A. Dasgupta, and F. Sotgia An absence of stromal caveolin-1 expression predicts early tumor recurrence and poor clinical outcome in human breast cancers Am J Pathol 174 6 2009 2023 2034
36. S.M. Gallagher, J.J. Castorino, D. Wang, and N.J. Philp Monocarboxylate transporter 4 regulates maturation and trafficking of CD147 to the plasma membrane in the metastatic breast cancer cell line MDA-MB-231 Cancer Res 67 9 2007 4182 4189
37. K.S. Dimmer, B. Friedrich, F. Lang, J.W. Deitmer, and S. Broer The low-affinity monocarboxylate transporter MCT4 is adapted to the export of lactate in highly glycolytic cells Biochem J. 350 Pt 1 2000 219 227
38. H. Pilegaard, G. Terzis, A. Halestrap, and C. Juel Distribution of the lactate/H+ transporter isoforms MCT1 and MCT4 in human skeletal muscle Am J Physiol 276 5 Pt 1 1999 E843 E848
39. J.E. Manning Fox, D. Meredith, and A.P. Halestrap Characterisation of human monocarboxylate transporter 4 substantiates its role in lactic acid efflux from skeletal muscle J Physiol 529 Pt 2 2000 285 293
40. F. Herubel, S. El Mouatassim, P. Guerin, R. Frydman, and Y. Menezo Genetic expression of monocarboxylate transporters during human and murine oocyte maturation and early embryonic development Zygote 10 2 2002 175 181
41. S. Jansen, T. Esmaeilpour, M. Pantaleon, and P.L. Kaye Glucose affects monocarboxylate cotransporter (MCT) 1 expression during mouse preimplantation development Reproduction 131 3 2006 469 479
42. S.J. Wakil, and L.A. Abu-Elheiga Fatty acid metabolism: target for metabolic syndrome J Lipid Res 50 Suppl:S 2009 138 143
43. P. Sonveaux, F. Vegran, and T. Schroeder Targeting lactate-fueled respiration selectively kills hypoxic tumor cells in mice J Clin Invest 118 12 2008 3930 3942
44. D. Whitaker-Menezes, U.E. Martinez-Outschoorn, and Z. Lin Evidence for a stromal-epithelial "lactate shuttle" in human tumors: MCT4 is a marker of oxidative stress in cancer-associated fibroblasts Cell Cycle 10 11 2011 1772 1783
45. S.E. Rademakers, J. Lok, A.J. van der Kogel, J. Bussink, and J.H. Kaanders Metabolic markers in relation to hypoxia; staining patterns and colocalization of pimonidazole, HIF-1alpha, CAIX, LDH-5, GLUT-1, MCT1 and MCT4 BMC Cancer 11 2011 167
46. K. Bluemlein, N.M. Gruning, R.G. Feichtinger, H. Lehrach, B. Kofler, and M. Ralser No evidence for a shift in pyruvate kinase PKM1 to PKM2 expression during tumorigenesis Oncotarget 2 5 2011 393 400
47. B. Chiavarina, D. Whitaker-Menezes, and U.E. Martinez-Outschoorn Pyruvate kinase expression (PKM1 and PKM2) in cancer-associated fibroblasts drives stromal nutrient production and tumor growth Cancer Biol Ther 12 12 2011 1101 1113
48. D. Anastasiou, G. Poulogiannis, and J.M. Asara Inhibition of pyruvate kinase M2 by reactive oxygen species contributes to cellular antioxidant responses Science 334 6060 2011 1278 1283
49. M.S. Ullah, A.J. Davies, and A.P. Halestrap The plasma membrane lactate transporter MCT4, but not MCT1, is up-regulated by hypoxia through a HIF-1alpha-dependent mechanism J Biol Chem 281 14 2006 9030 9037
50. S. Fulda, L. Galluzzi, and G. Kroemer Targeting mitochondria for cancer therapy Nat Rev Drug Discov 9 6 2010 447 464
51. V. Gogvadze, B. Zhivotovsky, and S. Orrenius The Warburg effect and mitochondrial stability in cancer cells Mol Aspects Med 31 1 2010 60 74
52. T. Kurosu, T. Fukuda, T. Miki, and O. Miura BCL6 overexpression prevents increase in reactive oxygen species and inhibits apoptosis induced by chemotherapeutic reagents in B-cell lymphoma cells Oncogene 22 29 2003 4459 4468
53. R.T. Phan, and R. Dalla-Favera The BCL6 proto-oncogene suppresses p53 expression in germinal-centre B cells Nature 432 7017 2004 635 639
54. S. Kusam, F.H. Vasanwala, and A.L. Dent Transcriptional repressor BCL-6 immortalizes germinal center-like B cells in the absence of p53 function Oncogene 23 3 2004 839 844
55. A. Chacinska, C.M. Koehler, D. Milenkovic, T. Lithgow, and N. Pfanner Importing mitochondrial proteins: machineries and mechanisms Cell 138 4 2009 628 644
56. C.A. Wurm, D. Neumann, M.A. Lauterbach, B. Harke, A. Egner, S.W. Hell, and S. Jakobs Nanoscale distribution of mitochondrial import receptor Tom20 is adjusted to cellular conditions and exhibits an inner-cellular gradient Proc Natl Acad Sci U S A 108 33 2011 13546 13551
57. A.R. Young, M. Narita, and M. Ferreira Autophagy mediates the mitotic senescence transition Genes Dev 23 7 2009 798 803
58. C.H. Eng, and R.T. Abraham The autophagy conundrum in cancer: influence of tumorigenic metabolic reprogramming Oncogene 30 47 2011 4687 4696
59. H. Dubouchaud, G.E. Butterfield, E.E. Wolfel, B.C. Bergman, and G.A. Brooks Endurance training, expression, and physiology of LDH, MCT1, and MCT4 in human skeletal muscle Am J Physiol Endocrinol Metab 278 4 2000 E571 9
60. K.M. Kennedy, and M.W. Dewhirst Tumor metabolism of lactate: the influence and therapeutic potential for MCT and CD147 regulation Future Oncol 6 1 2010 127 148
61. G. Lenz, and L.M. Staudt Aggressive lymphomas N Engl J Med 362 15 2010 1417 1429
62. M. Ziepert, D. Hasenclever, E. Kuhnt, B. Glass, N. Schmitz, M. Pfreundschuh, and M. Loeffler Standard International prognostic index remains a valid predictor of outcome for patients with aggressive CD20+ B-cell lymphoma in the rituximab era J Clin Oncol 28 14 2010 2373 2380
63. A predictive model for aggressive non-Hodgkin's lymphoma The International Non-Hodgkin's Lymphoma Prognostic Factors Project N Engl J Med 329 14 1993 987 994
64. J. Hermans, A.D. Krol, and K. van Groningen International Prognostic Index for aggressive non-Hodgkin's lymphoma is valid for all malignancy grades Blood 86 4 1995 1460 1463
65. L.H. Sehn, B. Berry, M. Chhanabhai, and C. Fitzgerald The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP Blood 109 5 2007 1857 1861
66. Y.F. He, W. Wei, and Z.M. Sun Fatal lactic acidosis and hypoglycemia in a patient with relapsed natural killer/T-cell lymphoma Adv Ther 24 3 2007 505 509
67. B. Levy Lactate and shock state: the metabolic view Curr Opin Crit Care 12 4 2006 315 321
68. C.O. Record, R.A. Iles, R.D. Cohen, and R. Williams Acid-base and metabolic disturbances in fulminant hepatic failure Gut 16 2 1975 144 149
69. S. Archer, and B. Bache-Wiig Lactic acidosis B associated with solid tumors Minn Med 69 9 1986 511 514
70. R.A. Kreisberg Lactate homeostasis and lactic acidosis Ann Intern Med 92 2 Pt 1 1980 227 237
71. N.E. Madias Lactic acidosis Kidney Int 29 3 1986 752 774
72. E. Leal-Pinto, H.C. Park, F. King, M. MacLeod, and R.F. Pitts Metabolism of lactate by the intact functioning kidney of the dog Am J Physiol 224 6 1973 1463 1467
73. J.M. Naylor, D.S. Kronfeld, D.E. Freeman, and D. Richardson Hepatic and extrahepatic lactate metabolism in sheep: effects of lactate loading and pH Am J Physiol 247 1984 747 755
74. J. Yudkin, and R.D. Cohen The effect of acidosis on lactate removal by the perfused rat kidney Clin Sci Mol Med 50 3 1976 185 194
75. S.R. Salpeter, E. Greyber, G.A. Pasternak, and E.E. Salpeter Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus Cochrane Database Syst Rev 4 2010 CD002967
76. C.J. Bailey, and R.C. Turner Metformin N Engl J Med 334 9 1996 574 579
77. L.C. Pelosof, and D.E. Gerber Paraneoplastic syndromes: an approach to diagnosis and treatment Mayo Clin Proc 85 9 2010 838 854
78. S.S. McAllister, and R.A. Weinberg Tumor-host interactions: a far-reaching relationship J Clin Oncol 28 26 2010 4022 4028
79. I. Carr The Ophelia syndrome: memory loss in Hodgkin's disease Lancet 1 8276 1982 844 845
80. T. Braik, A.T. Evans, M. Telfer, and S. McDunn Paraneoplastic neurological syndromes: unusual presentations of cancer. A practical review Am J Med Sci 340 4 2010 301 308
81. K.R. Daffner, J.C. Sherman, R.G. Gonzalez, and R.P. Hasserjian Case records of the Massachusetts General Hospital. Case 35-2008. A 65-year-old man with confusion and memory loss N Engl J Med 359 20 2008 2155 2164
82. S.H. Gultekin, M.R. Rosenfeld, R. Voltz, J. Eichen, J.B. Posner, and J. Dalmau Paraneoplastic limbic encephalitis: neurological symptoms, immunological findings and tumour association in 50 patients Brain 123 Pt 7 2000 1481 1494
83. R. Linke, and R. Voltz FDG-pet in paraneoplastic syndromes Recent Results Cancer Res 170 2008 203 211
84. S. Basu, and A. Alavi Role of FDG-PET in the clinical management of paraneoplastic neurological syndrome: detection of the underlying malignancy and the brain PET-MRI correlates Mol Imaging Biol 10 3 2008 131 137
85. D. Hanahan, and R.A. Weinberg Hallmarks of cancer: the next generation Cell 144 5 2011 646 674
86. G. Salles, J.F. Seymour, and F. Offner Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial Lancet 377 9759 2011 42 51
87. T.M. Habermann, E.A. Weller, and V.A. Morrison Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma J Clin Oncol 24 19 2006 3121 3127
88. B.T. Huang, Q.C. Zeng, J. Yu, Z. Xiao, B.S. Li, C.L. Zhang, and H.B. Ji How to determine post-RCHOP therapy for risk-tailored adult patients with diffuse large B-cell lymphoma, addition of maintenance rituximab or observation: multicenter experience J Cancer Res Clin Oncol 138 1 2012 125 132
89. Non-Hodgkin Lymphoma. National Comprehensive Cancer Network (NCCN) Clinical Practice GuidelinesVersion 1.2013. http://www.nccn.org/professionals/ physician-gls/pdf/nhl.pdf. Accessed March. 20th. 2013.
90. A. Greb, J. Bohlius, S. Trelle, and D. Schiefer High-dose chemotherapy with autologous stem cell support in first-line treatment of aggressive non-Hodgkin lymphoma - results of a comprehensive meta-analysis Cancer Treat Rev 33 4 2007 338 346
91. Stiff P. Randomized phase III U.S./Canadian intergroup trial (SWOG S9704) comparing CHOP+R for six cycles followed by autotransplant for patients with high-intermediate (H-Int) or high IPI grade diffuse aggressive non-Hodgkin lymphoma (NHL). ASCO Annual Meeting Abstract. Chicago, IL; June 2011.
92. J.D. Mancias, and A.C. Kimmelman Targeting autophagy addiction in cancer Oncotarget 2 12 2011 1302 1306
93. P. Maycotte, S. Aryal, C.T. Cummings, J. Thorburn, M.J. Morgan, and A. Thorburn Chloroquine sensitizes breast cancer cells to chemotherapy independent of autophagy Autophagy 8 2 2012 200 212
94. Lambin P. Chloroquine as an anti-autophagy drug in stage IV small cell lung cancer (SCLC) Patients. In: Clinicaltrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2010- [cited. 2013 March. 20]. Available from: http://clinicaltrials.gov/show/NCT00969306 NLM identifier: NCT00969306.
95. C. Renner, P.L. Zinzani, and R. Gressin A multicenter phase II trial (SAKK 36/06) of single-agent everolimus (RAD001) in patients with relapsed or refractory mantle cell lymphoma Haematologica 97 7 2012 1085 1091
96. Mackenzie M. Metformin and temsirolimus in treating patients with metastatic or unresectable solid tumor or lymphoma. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2010- [cited. 2013 March. 20]. Available from: http://clinicaltrials.gov/show/NCT00659568 NLM Identifier: NCT00659568.
97. C. Pott, C. Schrader, and S. Gesk Quantitative assessment of molecular remission after high-dose therapy with autologous stem cell transplantation predicts long-term remission in mantle cell lymphoma Blood 107 6 2006 2271 2278
98. P. Corradini, M. Astolfi, and C. Cherasco Molecular monitoring of minimal residual disease in follicular and mantle cell non-Hodgkin's lymphomas treated with high-dose chemotherapy and peripheral blood progenitor cell autografting Blood 89 2 1997 724 731
99. M. Uchiyama, C. Maesawa, and A. Yashima Development of consensus fluorogenically labeled probes of the immunoglobulin heavy-chain gene for detecting minimal residual disease in B-cell non-Hodgkin lymphomas Cancer Sci 94 10 2003 877 885
100. C.H. Moskowitz, H. Schoder, and J. Teruya-Feldstein Risk-adapted dose-dense immunochemotherapy determined by interim FDG-PET in advanced-stage diffuse large B-cell lymphoma J Clin Oncol 28 11 2010 1896 1903
101. S.J. Horning, M.E. Juweid, and H. Schoder Interim positron emission tomography scans in diffuse large B-cell lymphoma: an independent expert nuclear medicine evaluation of the Eastern Cooperative Oncology Group E3404 study Blood 115 4 2010 775 777 quiz 918
102. P. Herrero, C.S. Dence, A.R. Coggan, Z. Kisrieva-Ware, P. Eisenbeis, and R.J. Gropler L-3-11C-lactate as a PET tracer of myocardial lactate metabolism: a feasibility study J Nucl Med 48 12 2007 2046 2055
103. J.D. Tward, M.M. Wendland, D.C. Shrieve, A. Szabo, and D.K. Gaffney The risk of secondary malignancies over 30 years after the treatment of non-Hodgkin lymphoma Cancer 107 1 2006 108 115
104. L.M. Morton, R.E. Curtis, and M.S. Linet Second malignancy risks after non-Hodgkin's lymphoma and chronic lymphocytic leukemia: differences by lymphoma subtype J Clin Oncol 28 33 2010 4935 4944
105. C. Tarella, R. Passera, and M. Magni Risk factors for the development of secondary malignancy after high-dose chemotherapy and autograft, with or without rituximab: a. 20-year retrospective follow-up study in patients with lymphoma J Clin Oncol 29 7 2011 814 824
106. K.C. Oeffinger, M.M. Hudson, and A.C. Mertens Increasing rates of breast cancer and cardiac surveillance among high-risk survivors of childhood Hodgkin lymphoma following a mailed, one-page survivorship care plan Pediatr Blood Cancer 56 5 2010 818 824
107. J.M. Evans, L.A. Donnelly, A.M. Emslie-Smith, D.R. Alessi, and A.D. Morris Metformin and reduced risk of cancer in diabetic patients Bmj 330 7503 2005 1304 1305
108. N. Akyurek, A. Uner, M. Benekli, and I. Barista Prognostic significance of MYC, BCL2, and BCL6 rearrangements in patients with diffuse large B-cell lymphoma treated with cyclophosphamide, doxorubicin, vincristine, and prednisone plus rituximab Cancer 118 17 2012 4173 4183
109. S. Barrans, S. Crouch, and A. Smith Rearrangement of MYC is associated with poor prognosis in patients with diffuse large B-cell lymphoma treated in the era of rituximab J Clin Oncol 28 20 2010 3360 3365
110. K.J. Savage, N.A. Johnson, and S. Ben-Neriah MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy Blood 114 17 2009 3533 3537
111. C. Haioun, E. Lepage, and C. Gisselbrecht Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin's lymphoma: final analysis of the prospective LNH87-2 protocol - -a groupe d'Etude des lymphomes de l'Adulte study J Clin Oncol 18 16 2000 3025 3030
112. A.G. Singal, H.S. Conjeevaram, and M.L. Volk Effectiveness of hepatocellular carcinoma surveillance in patients with cirrhosis Cancer Epidemiol Biomarkers Prev 21 5 2012 793 799